Sporadic fundic gland polyps with dysplasia or carcinoma:Clinical and endoscopic characteristics  

作　　者：Wataru Sano Fumihiro Inoue Daizen Hirata Mineo Iwatate Santa Hattori Mikio Fujita Yasushi Sano 

机构地区：[1]Gastrointestinal Center,Sano Hospital,Kobe 655-0031,Hyogo,Japan

出　　处：《World Journal of Gastrointestinal Oncology》2021年第7期662-672,共11页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：Fundic gland polyps(FGPs)are the most common gastric polyps and have been regarded as benign lesions with little malignant potential,except in the setting of familial adenomatous polyposis.However,in recent years,the prevalence of FGPs has been increasing along with the widespread and frequent use of proton pump inhibitors(PPIs).To date,several cases of FGPs with dysplasia or carcinoma(FGPD/CAs)have been reported.In this review,we evaluated the clinical and endoscopic characteristics of sporadic FGPD/CAs.Majority of the patients with sporadic FGPD/CAs were middle-aged women receiving PPI therapy and without Helicobacter pylori(H.pylori)infection.Majority of the sporadic FGPD/CAs occurred in the body of the stomach and were sessile and small with a mean size of 5.4 mm.The sporadic FGPs with carcinoma showed redness,irregular surface structure,depression,or erosion during white light observation and irregular microvessels on the lesion surface during magnifying narrow-band imaging.In addition,sporadic FGPs,even with dysplasia,are likely to progress to cancer slowly.Therefore,frequent endoscopy is not required for patients with sporadic FGPs.However,histopathological evaluation is necessary if endoscopic findings different from ordinary FGPs are observed,regardless of their size.In the future,the prevalence of FGPs is expected to further increase along with the widespread and frequent use of PPIs and decreasing infection rate of H.pylori.Currently,it is unclear whether FGPD/CAs will also increase in the same way as FGPs.However,the trends of these lesions warrant further attention in the future.

关 键 词：SPORADIC Fundic gland polyp DYSPLASIA CARCINOMA Proton pump inhibitor Helicobacter pylori 

分 类 号：R735.2[医药卫生—肿瘤]